Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
Generated Narrative: Evidence 236967
version: 63; Last updated: 2024-12-14 08:46:28+0000
Profile: ComparatorOnlyEvidence
url: https://fevir.net/resources/Evidence/236967
identifier: FEvIR Object Identifier/https://fevir.net/FOI/236967, outcomeId/313960, picoId/85798, sectionId/73215
name: End_stage_kidney_disease_Comparator_Evidence_from_MAGICapp_313960
title: MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes
status: Active
publisher: Computable Publishing LLC
contact: support@computablepublishing.com
author: Computable Publishing®: MAGIC-to-FEvIR Converter:
Code | Value[x] |
Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication: Evidence Communication | ComparatorOnlyEvidence |
copyright:
https://creativecommons.org/licenses/by-nc-sa/4.0/
Type | ResourceReference |
Part Of | MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report) |
description:
This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.
note: Defined as a GFR below 45 or a GFR below 70 AND macroalbuminuria (ACR > 200 mg/g); derived from RECODe (https://sanjaybasu.shinyapps.io/recode/).
variableDefinition
description:
Adults with type 2 diabetes -- GLP-1 RA
variableRole: Population
variableDefinition
description:
End-stage kidney disease
variableRole: Outcome
observed: End-stage kidney disease
synthesisType: NOTSET
studyDesign: NO_STUDY
Description | StatisticType | Quantity |
Risk 11.9% | Proportion | 0.119 |